Introduction {#s1}
============

Cancer is a significant health problem in many parts of the worldwide [@pone.0103593-Jemal1], [@pone.0103593-Witz1]. In Korea, the incidence rate of breast cancer was ranked second and the mortality rate fifth in Korean women, which steadily increased from 1983 to 2010 [@pone.0103593-Jung1]. The etiology and progression of breast cancer is a multiple-step process caused by combining many factors which involve environmental, hormonal and genetic factors [@pone.0103593-Key1], [@pone.0103593-Sariego1]. We focused on genetic factors involved in immune response which was known to play a role in breast cancer prognosis.

The association of immune markers with breast cancer prognosis were well known and the role as key factor of microenvironment of tumor such as tumor suppressor or growth. For example, high density of CD68 which is high-infiltration of tumor-associated macrophages was related with poorer outcome in node-negative breast cancer [@pone.0103593-Zhang1] and CD44 positive patients showed longer overall survival and progression free survival than CD44 negative patients [@pone.0103593-Dan1]. In addition, cytokines produced by various immune cells were known to modulate the transition from the innate to the adaptive immune response, the activation of anti-tumor cells, persistent oxidative stress, and the angiogenesis of breast cancer [@pone.0103593-Mori1]--[@pone.0103593-Schreibelt1]. The prognosis of breast cancer was also known to be associated with single nucleotide polymorphisms (SNPs) in the immune system related genes [@pone.0103593-Yang1]--[@pone.0103593-DeMichele1]. Those reports described that genetic variants of toll-like receptor 4 (*TLR4*), interleukin 12 (*IL-12*), interleukin 2 (*IL-2*), and interleukin 6 (*IL-6*) were related with breast cancer prognosis. However, there have been few studies that investigate the association between comprehensive list of variants in the immunity-related genes and the prognosis of breast cancer.

Given the findings that immune system is related with breast cancer prognosis, we hypothesized that many genetic polymorphisms in immune related genes might be prognostic factor of breast cancer recurrence. In this study, the role of common immune genetic variations to the disease free survival (DFS) of breast cancer was investigated with the multivariate Cox-proportional hazard model by individual variants, polygenic risk score model, and an extended gene set enrichment analysis. Additionally, a systematic review of previous literature that had reported on the associations between variants of the immunity-related genes and the prognosis of various cancers was done.

Materials and Methods {#s2}
=====================

Study population {#s2a}
----------------

Among subjects of Seoul Breast Cancer Study (SEBCS), a multicenter based case-control study recruiting between 2001 and 2007, the participants in this study were patients diagnosed with histologically confirmed breast cancer in the Seoul National University Hospital during 2002--2004. Based on the sample availability and quality of DNA, 140 breast cancer patients were successfully genotyped [@pone.0103593-Lee1]. Among them, 107 patients were included in the final analysis after excluding patients without survival status or clinical information or been diagnosed as metastatic breast cancer patients.

During recruitment, well-trained interviewers provided patients with informed consent forms and collected information with a structured questionnaire. Through abstracting the medical chart, information on survival status, hormone receptor status, and TNM stage [@pone.0103593-Boyle1] were obtained.

This study design was approved by the Committee on Human Research of Seoul National University Hospital (IRB No. H-0503-144-004).

Genotyping {#s2b}
----------

Among 209 samples met the genotyping criteria (concentration \>7.5 ng/ul and total amount of DNA \>750 ng), 140 cases were successfully genotyped. 283 immune-related candidate genes were composed of 190 innate immune-related genes in innate immune oligonucleotide pool assay (OPA) chip and 93 adaptive immune-related genes in Non-Hodgkin's lymphoma (NHL) OPA chip as described in previous study [@pone.0103593-Lee1], [@pone.0103593-Park1]. 2,432 Tags SNPs were selected with SNP500 Cancer project database considering the site from 20 kb upstream of the first site of transcription of a candidate gene to 10 kb downstream of the end site of the last exon of the candidate gene and genotyped. Among them, 461 SNPs were excluded from the analysis because of low minor allele frequency (MAF) (\<3%) and deviation from Hardy-Weinberg Equilibrium (HWE) (*P\<*10^−4^). Finally, a total of 1,971 SNPs in 279 immunity genes were selected for the analysis.

Statistical method {#s2c}
------------------

A DFS was calculated from the date when patients underwent a breast cancer operation to the date of last follow-up or recurrence, such as loco-regional, distant, contralateral recurrence and death from any causes. If patients had no evidence of recurrence, they were censored at the last follow-up date or on June 30, 2011. The median follow-up time was 4.87 years (range, 0.25--6.72 years).

Demographic data including age (\<50 and ≥50), body mass index (BMI) (\<21.4 and ≥21.4), family history of breast cancer in 1^st^ and 2^nd^ relatives (no and yes), educational level (≤ middle school, high school, and ≥ college or university), smoking status (never and ever), alcohol consumption (never and ever), and menopausal status (premenopausal and postmenopausal), and clinicopathological data including estrogen receptor status (ER) (positive and negative), progesterone receptor status (PR) (positive and negative), and 7^th^ AJCC TNM stage (I, II, and III) were assessed for DFS with the log-rank test and univariate Cox-proportional hazard model. Multivariate Cox-proportional hazard model adjusted for age, ER status, PR status, and TNM stage (I, II, and III) was used to calculate the hazard ratio (HR) and their 95% CI of the effect for each SNP on the DFS of breast cancer based on additive genetic models. If SNPs were located in the same candidate gene and these SNPs had a linkage disequilibrium (LD) (r^2^\>0.4), the most significantly associated SNP were selected. To correct the multiple comparison, false discovery rate (FDR) *p*-values were calculated with the Benjamin-Hochberg method [@pone.0103593-Benjamini1].

For the polygenic risk score method, the polygenic risk score was calculated by adding the number of risk alleles in each patient based on individual SNP analyses and the patients were categorized into tertiles of polygenic risk score [@pone.0103593-Reeves1]. HR and 95% confidence intervals (CIs) per tertile of polygenic risk score were calculated. After analyzing multivariate Cox-proportional hazard model, Harrell's C index was calculated to evaluate predictive accuracy of polygenic risk score model [@pone.0103593-Harrell1]. In addition, 4-fold cross-validation method was used to appraise the internal validity of our model; the entire data set was randomly partitioned into 4 equal size subsets. Of the 4 subsets, 3 subsets were used as training data, and a remaining single subset was retained as the validation data for testing the model. Significantly associated SNPs with prognosis of breast cancer were firstly estimated in training set and then Harrell's C index was estimated based on those SNPs in validation set. The cross-validation process was then repeated 4 times. The summary of these 4 Harrell's indices was assessed by fixed-effect model meta-analysis.

The GSEA-SNP method was used to reveal the biological function of the SNPs which were significantly related to breast cancer prognosis [@pone.0103593-Holden1]. Pathway information was obtained from the Molecular Signatures Database (MSigDB) which collected annotated gene sets from the following online databases; BioCarta, KEGG, Pathway Interaction Database, Reactome, SigmaAldrich, Signaling Gateway, Signal Transduction KE, and SuperArray. In addition, gene sets that have been extracted from experimental studies were included in the database. The curated gene sets were downloaded from MSigDB (version 4.0, C2). Because there was a chance of the biological pathway being narrowly defined, each pathway was set up to contain at least three genes in the following analyses. The names of gene sets were described with 'brief description' rather than 'standard name' which is available on the GSEA web (<http://www.broadinstitute.org/gsea/index.jsp>), because standard name equivocally explained function of gene set.

The statistical significance of the effects was estimated with a *p-*value less than 0.05 in both multivariate Cox-proportional hazard model by individual variants and polygenic risk score models and 0.1 in GSEA-SNP. The SAS statistical software package version 9.3, PLINK program version 1.07, and R 2.15.1 packages (GenABEL), STATA statistical software version 12.0 were used for the analyses.

Systematic review {#s2d}
-----------------

Previous studies conducting analyses to find associations between immunity-related genetic factors and the prognosis of cancer in the epidemiologic field were selected for Jan 2000 through Dec 2013 ([Figure 2](#pone-0103593-g002){ref-type="fig"}). Available studies for systematic review were searched in the PubMed and EMBASE database with a set of keywords that delineated breast cancer as well as other cancers, immune, genetic factors, and survival; cancer AND immune AND polymorphism AND survival. Abstracts were reviewed to identify reports examining associations between immunity-related genetic factors and clinical outcomes including recurrence and death. Literatures were excluded in the following circumstances; review paper, studies unrelated with genomic epidemiology, using SNPs located in non-immune related genes, duplicated in both databases, with no survival or recurrence data reported for survival analysis and no hazard ratios (HRs) reported which were estimated with the Cox-proportional hazard model for the associations of immunity-related genetic factors with cancer outcomes ([Figure 2](#pone-0103593-g002){ref-type="fig"}). In cases of duplication between both databases, the studies were deemed to have been searched in the PubMed database. The following data were extracted from each eligible study from the literature; disease site, authors, genes assessed, number of polymorphisms assessed, number of patients and events including recurrence, death, follow-up period, type of outcome, and covariates. Associations between polymorphisms and the outcome of each cancer were recorded as HR with 95% CI and adjustments. Because different nomenclatures and names for polymorphisms were used in the studies, all polymorphisms were named by RefSNP (rs) numbers. We followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement and checklist as a methodological template for this review ([Table S1](#pone.0103593.s001){ref-type="supplementary-material"}).

Results {#s3}
=======

[Table 1](#pone-0103593-t001){ref-type="table"} shows the characteristics of the 107 patients including 20 patients who had the events. Among the 107 cases, BMI, PR status, and TNM stage showed a significant association with the prognosis on the DFS of breast cancer (*P*\<0.05, log-rank test), while there were no significant differences in age, family history of breast cancer, educational level, menopausal status, smoking status, alcohol consumption, and ER status.

10.1371/journal.pone.0103593.t001

###### Characteristic of study participants.

![](pone.0103593.t001){#pone-0103593-t001-1}

  Characteristics                 No. of patients (%)   No. of events (%)   *P* [a](#nt101){ref-type="table-fn"}   HR[b](#nt102){ref-type="table-fn"}     (95% CI)      *P* [b](#nt102){ref-type="table-fn"}
  ------------------------------ --------------------- ------------------- -------------------------------------- ------------------------------------ --------------- --------------------------------------
  Total                               107 (100.0)          20 (100.0)                                                                                                  
  Age (Mean ± SD)                      50.6±8.2             52.5±10.6                       0.60                                                                       
  \<50                                 54 (50.5)            11 (55.0)                                                             1.00                                 
  ≥50                                  53 (49.5)            9 (45.0)                                                              0.79                  (0.33--1.91)                    0.60
  Body mass index (Mean ± SD)          23.7±2.9             24.4±2.13                      \<0.02                                                                      
  \<21.4 (median)                      30 (33.3)             1 (5.0)                                                              1.00                                 
  ≥21.4                                77 (66.7)            19 (95.0)                                                             7.30                  (0.98--54.61)                   0.05
  Family history                                                                            1.00                                                                       
  No                                   97 (90.7)            18 (90.0)                                                             1.00                                 
  Yes                                  10 (9.3)             2 (10.0)                                                              1.00                  (0.23--4.37)                    1.00
  Educational level                                                                         0.46                                                                       
  ≤Middle school                       30 (28.3)            4 (20.0)                                                              1.00                                 
  High school                          46 (43.4)            11 (55.0)                                                             1.95                  (0.62--6.13)                    0.26
  ≥College or university               30 (28.3)            5 (25.0)                                                              1.27                  (0.34--4.73)                    0.72
  Menopausal status                                                                         0.71                                                                       
  Premenopausal                        62 (58.5)            11 (55.0)                                                             1.00                                 
  Postmenopausal                       44 (41.5)            9 (45.0)                                                              1.18                  (0.49--2.84)                    0.72
  Smoking status                                                                            0.10                                                                       
  Never                               100 (93.5)            17 (85.0)                                                                                                  
  Ever                                  7 (6.5)             3 (15.0)                                                              2.70                  (0.78--9.17)                    0.12
  Alcohol consumption                                                                       0.66                                                                       
  Never                                70 (65.4)            14 (70.0)                                                                                                  
  Ever                                 37 (34.6)            6 (30.0)                                                              0.81                  (0.31--2.10)                    0.66
  Estrogen receptor status                                                                  0.07                                                                       
  Positive                             66 (62.3)            9 (45.0)                                                              1.00                                 
  Negative                             40 (37.7)            11 (55.0)                                                             2.19                  (0.90--5.28)                    0.08
  Progesterone receptor status                                                              0.01                                                                       
  Positive                             53 (50.5)            5 (25.0)                                                              1.00                                 
  Negative                             52 (49.5)            15 (75.0)                                                             3.39                  (1.23--9.37)                    0.02
  TNM stage                                                                                \<0.01                                                                      
  0/I                                  48 (45.3)            4 (20.0)                                                              1.00                                 
  II                                   40 (37.7)            7 (35.0)                                                              2.20                  (0.64--7.56)                    0.21
  III                                  18 (17.0)            9 (50.0)                                                              8.54                  (2.62--27.88)                  \<0.01

Log rank test.

Univariate Cox-proportional hazard model.

The associations of immunity-related genetic factors on DFS of breast cancer prognosis are presented in [Table 2](#pone-0103593-t002){ref-type="table"}. Among 1,971 SNPs, 80 SNPs were significantly associated with the DFS of breast cancer. The 62 SNPs were remained after excluding those with high LD (r^2^\>0.4) and 3 SNPs were still significant at FDR p-value less than 0.05. The SNPs were rs1952438 in *SOCS4* gene (HR = 11.99, 95% CI = 3.62--39.72, *P* = 4.84E-05), rs2289278 in *TSLP* gene (HR = 4.25, 95% CI = 2.10--8.62, *P* = 5.99E-05) and rs2074724 in *HGF* gene (HR = 4.63, 95% CI = 2.18--9.87, *P* = 7.04E-05).

10.1371/journal.pone.0103593.t002

###### Associations between the genetic variations of immunity-related genes and breast cancer disease free survival in the additive model (significance level, *P*\<5.00E-02).
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  Gene              Location         SNP       MAF    HR[a](#nt103){ref-type="table-fn"}     (95% CI)        *P*
  ------------- ---------------- ------------ ------ ------------------------------------ --------------- ----------
  *SOCS4*           intronic      rs1952438    0.04                 11.99                  (3.62--39.72)   4.84E-05
  *TSLP*              UTR5        rs2289278    0.15                  4.25                  (2.10--8.62)    5.99E-05
  *HGF*             intronic      rs2074724    0.11                  4.63                  (2.18--9.87)    7.04E-05
  *IL-17C*          intronic      rs2254073    0.15                  4.24                  (1.90--9.49)    4.31E-04
  *BCL2*           intergenic     rs9989529    0.19                  3.80                  (1.63--8.84)    1.98E-03
  *CCL2*           intergenic     rs17652343   0.08                  4.57                  (1.74--11.97)   2.01E-03
  *ITGB2*           intronic      rs2838727    0.04                  6.57                  (1.84--23.44)   3.70E-03
  *TRAF2*          intergenic      rs908831    0.14                  3.79                  (1.54--9.36)    3.79E-03
  *NBN*            downstream     rs2142097    0.42                  3.55                  (1.48--8.49)    4.40E-03
  *SELE*           intergenic     rs4656701    0.35                  0.28                  (0.11--0.71)    7.41E-03
  *CCR1*           downstream     rs3136671    0.19                  3.05                  (1.33--7.00)    8.47E-03
  *HGF*             intronic      rs5745752    0.33                  0.29                  (0.11--0.73)    9.22E-03
  *IL-12A*         intergenic     rs9811792    0.31                  0.23                  (0.08--0.71)    1.01E-02
  *MIF*           ncRNA_exonic    rs1007888    0.41                  2.39                  (1.22--4.67)    1.11E-02
  *ITGB2-AS1*     ncRNA_exonic    rs2070946    0.12                  2.98                  (1.28--6.93)    1.11E-02
  *MIF*          ncRNA_intronic   rs2000466    0.18                  3.37                  (1.32--8.60)    1.12E-02
  *ALOXE3*          intronic      rs3027215    0.07                  3.17                  (1.28--7.87)    1.27E-02
  *IFNAR2*          intronic      rs2073362    0.15                  3.86                  (1.33--11.17)   1.28E-02
  *XDH*            intergenic     rs10490361   0.46                  0.44                  (0.23--0.84)    1.35E-02
  *CCL8*           intergenic     rs3138034    0.07                  3.59                  (1.29--9.96)    1.42E-02
  *SOCS2*           intronic      rs3782415    0.48                  2.38                  (1.18--4.83)    1.60E-02
  *DEF6*            intronic      rs6938946    0.34                  2.26                  (1.16--4.39)    1.68E-02
  *ABHD16A*         intronic      rs2295663    0.10                  2.55                  (1.16--5.59)    1.93E-02
  *LBP*             intronic      rs12624843   0.30                  0.33                  (0.13--0.84)    2.03E-02
  *IL-18*          intergenic      rs243908    0.33                  3.59                  (1.22--10.61)   2.05E-02
  *IL-10RB*           UTR3        rs1058867    0.32                  2.62                  (1.14--6.04)    2.33E-02
  *IL-6R*          intergenic     rs11265608   0.04                  4.15                  (1.21--14.21)   2.36E-02
  *IRAK4*           intronic      rs4251460    0.11                  2.78                  (1.15--6.73)    2.38E-02
  *TRAF5*           intronic      rs6684874    0.29                  0.29                  (0.10--0.85)    2.46E-02
  *MIF*          ncRNA_intronic   rs17004044   0.17                  0.23                  (0.06--0.83)    2.48E-02
  *XDH*             intronic      rs1429372    0.38                  0.43                  (0.20--0.91)    2.70E-02
  *LMAN1*           intronic      rs12953981   0.41                  0.41                  (0.19--0.91)    2.74E-02
  *ALOXE3*          intronic      rs3027208    0.43                  0.44                  (0.21--0.91)    2.76E-02
  *CCL11*          intergenic     rs4795904    0.08                  3.11                  (1.13--8.56)    2.81E-02
  *IL-12B*         intergenic     rs4921468    0.22                  2.54                  (1.10--5.87)    2.85E-02
  *IL-4R*             UTR3          rs8832     0.42                  0.39                  (0.17--0.91)    2.85E-02
  *IL-12A*         intergenic      rs747825    0.15                  0.10                  (0.01--0.79)    2.90E-02
  *SCNN1A*          intronic      rs3759324    0.36                  2.10                  (1.07--4.14)    3.03E-02
  *ITGB2*           intronic      rs1474552    0.23                  0.26                  (0.08--0.88)    3.06E-02
  *C6*              intronic      rs13168926   0.40                  0.40                  (0.18--0.92)    3.08E-02
  *FGF2*           intergenic      rs308447    0.08                  2.89                  (1.09--7.65)    3.25E-02
  *IL-10*           intronic      rs3021094    0.42                  0.40                  (0.17--0.93)    3.26E-02
  *SELE*           intergenic     rs4656699    0.20                  0.31                  (0.11--0.92)    3.41E-02
  *STK19*           intronic       rs389883    0.26                  1.96                  (1.05--3.67)    3.46E-02
  *STAT4*           intronic      rs1031509    0.31                  0.43                  (0.19--0.94)    3.53E-02
  *NCF4*            intronic      rs2075938    0.39                  2.17                  (1.05--4.51)    3.66E-02
  *SLC2A11*        intergenic     rs1984309    0.39                  0.44                  (0.20--0.95)    3.68E-02
  *BPI*             intronic      rs2275954    0.40                  2.19                  (1.05--4.59)    3.70E-02
  *TNFRSF1A*        intronic      rs4149577    0.41                  0.37                  (0.14--0.94)    3.70E-02
  *KLK15*           upstream      rs3745523    0.29                  2.07                  (1.04--4.12)    3.81E-02
  *BCL2*            intronic      rs12458289   0.28                  2.27                  (1.04--4.96)    4.00E-02
  *MBL2*           intergenic     rs11003134   0.20                  8.09                  (1.08--60.37)   4.16E-02
  *BCL10*          intergenic     rs6693365    0.30                  2.36                  (1.03--5.39)    4.18E-02
  *SELE*            intronic      rs3917412    0.28                  2.13                  (1.03--4.40)    4.21E-02
  *CD180*          intergenic     rs6890674    0.15                  2.27                  (1.03--5.02)    4.29E-02
  *MAL*             intronic      rs3113002    0.35                  0.45                  (0.21--0.98)    4.30E-02
  *AICDA*             UTR3        rs11046349   0.12                  2.81                  (1.03--7.69)    4.44E-02
  *C1QA*            intronic      rs2935542    0.14                  2.29                  (1.02--5.13)    4.49E-02
  *IRF4*           intergenic     rs11242867   0.29                  2.16                  (1.02--4.61)    4.50E-02
  *IL-8*           intergenic     rs4694178    0.40                  0.48                  (0.23--0.99)    4.61E-02
  *MASP1*           intronic      rs3105782    0.15                  2.30                  (1.01--5.24)    4.70E-02
  *MUC2*           intergenic     rs4077757    0.03                  3.88                  (1.01--14.90)   4.80E-02

Multivariate Cox proportional hazard model adjusted for age, estrogen receptor status, progesterone receptor status and TNM stage.

[Figure 1](#pone-0103593-g001){ref-type="fig"} presents the Kaplan-Meier survival curve and estimated HRs of breast cancer in groups defined by tertile derived from the polygenic risk scores of the 107 patients with all 62 SNPs. The HR was significantly increased as the score increased (*p* for trend = 0.01). The HR of women in the 3^rd^ tertile was 6.78 (95% CI = 1.48--31.06) compared to patients in the 1^st^ tertile of polygenic risk score. [Table 3](#pone-0103593-t003){ref-type="table"} shows the predictive accuracy and validation results of polygenic risk score model. The Harrell's C index of total patients is 0.813, and summarized Harrell's C index of cross validation is 0.924.

![Associations of the polygenic risk score on breast cancer disease free survival.\
Kaplan-Meier survival curve and estimated hazard ratios (HRs) of breast cancer in groups defined by tertile derived from the polygenic risk scores of the 107 patients with all 62 SNPs.](pone.0103593.g001){#pone-0103593-g001}

![Overview of inclusion and exclusion criteria in systematic review.](pone.0103593.g002){#pone-0103593-g002}

10.1371/journal.pone.0103593.t003

###### Harrell's C index for polygenic risk score estimated by 4-fold cross-validation.
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  Group                                      No. of SNPs in CV set   Harrell's C index   Standard error     (95% CI)
  ----------------------------------------- ----------------------- ------------------- ---------------- --------------
  All                                                                      0.813              0.48        (0.72--0.91)
  CV set1                                             25                   0.885              0.09        (0.70--1.07)
  CV set2                                             40                   0.910              0.06        (0.78--1.04)
  CV set3                                             32                   0.940              0.03        (0.88--1.00)
  CV set4                                             36                   0.909              0.04        (0.82--1.00)
  Summary[a](#nt104){ref-type="table-fn"}                                  0.924              0.02        (0.88--0.97)

The summary of Harrell's C index for 4 test sets calculated by fixed-effect meta-analysis.

In GSEA-SNP analysis, our results showed that 18 pathways with 62 SNPs in 56 immunity-related genes had significant association with the DFS of breast cancer at a *p*-value less than 0.1 ([Table 4](#pone-0103593-t004){ref-type="table"}); set 'Myc targets1': targets of c-Myc identified by ChIP on chip in cultured cell lines, focusing on E-box-containing genes; high affinity bound subset (including *BCL2* and *NBN*, *P* = 0.04), mitochondrial genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets (including *BCL2* and *NBN*, *P* = 0.04), genes down-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress (including *BCL2* and *CCL2*, *P* = 0.04), genes transiently induced only by the second pulse of *EGF* in 184A1 cells (mammary epithelium) (including *IRF3*, *TRAF5*, *KLK15* and *IL5R*, *P* = 0.02).

10.1371/journal.pone.0103593.t004

###### Pathway analysis for immune related genes on breast cancer disease free survival using GSEA-SNP method (*P*\<0.1).
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  Included genes (No. of SNPs)                                   HR^a^     (95% CI)     Enrichment Score   Normal *P* [b](#nt106){ref-type="table-fn"}                                                                                                                   Gene set (pathway)                                                                                                                       Reference       
  ------------------------------------------------------------- ------- -------------- ------------------ --------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ----------------------------
  *BCL2* (2), *NBN* (1)                                          2.65    (1.69--4.14)        0.8594                           0.04                                                                      Set 'Myc targets1': targets of c-Myc identified byChIP on chip in cultured cell lines, focusing onE-box-containing genes; high affinity bound subset                                                  Benporath *et al.*   [@pone.0103593-BenPorath1]
                                                                                                                                                                                                                      Mitochondrial genes; based on literature and sequenceannotation resources and converted to AffymetrixHG-U133A probe sets                                                                 Mootha *et al.*      [@pone.0103593-Mootha1]
  *BCL2* (2), *CCL2* (1)                                         3.12    (1.98--4.90)        0.8438                           0.04                                                                                             Genes down-regulated in T24 (bladder cancer) cells inresponse to the photodynamic therapy (PDT) stress                                                                         Buytaert *et al.*       [@pone.0103593-Liu2]
  *TSLP* (1), *BCL* (2), *TRAF5* (1), *MASP1* (1)                2.29    (1.59--3.32)        0.7392                           0.06                                                                                                                        Genes down-regulated in prostate cancer samples                                                                                                        Liu *et al.*      [@pone.0103593-Buytaert1]
  *SOCS4* (1), *HGF* (2)                                         2.39    (1.73--3.29)        0.8552                           0.07                                                                           Human environmental stress response genes notchanged in primary fibroblasts from Wilmorsyndrom (WS) patients in response to 4NQO treatment                                                         Kyng *et al.*        [@pone.0103593-Kyng1]
                                                                                                                                                                                                                       Human environmental stress response genes notchanged in primary fibroblasts from old donors inresponse to UV radiation                                                                   Kyng *et al.*        [@pone.0103593-Kyng1]
  *TSLP* (1), *ALOXE3* (2), *BCL2* (2), *MAL* (1), *IRF4* (1)    1.94    (1.49--2.52)        0.7163                           0.08                                                                    Set 'H3K27 bound': genes posessing the trimethylatedH3K27 (H3K27me3) mark in their promoters inhuman embryonic stem cells, as identified by ChIPon chip.                                                Benporath *et al.*   [@pone.0103593-BenPorath1]
  *TSLP* (1), *ALOXE3* (2), *BCL2* (2), *MAL* (1)                1.99    (1.52--2.62)        0.7393                           0.08                                                                                 Set 'Suz12 targets': genes identified by ChIP onchip as targets of the Polycomb protein *SUZ12* inhuman embryonic stem cells.                                                              Benporath *et al.*   [@pone.0103593-BenPorath1]
  *HGF* (2), *BCL2* (2)                                          2.48    (1.71--3.60)        0.7734                           0.09                                                                                                                                         Focal adhesion                                                                                                                            KEGG          [@pone.0103593-Kanehisa1]
                                                                                             0.7734                           0.09                                                                                                                                      Direct p53 effectors                                                                                                                         PID           [@pone.0103593-Schaefer1]
  *BCL2* (2), *LBP* (1)                                          2.57    (1.66--3.97)        0.8136                           0.09                                                                        Genes in the expression cluster 'Early ProgenitorsShared': up-regulated in hematopoietic progenitorsfrom adult bone marrow and from fetal liver.                                                     Ivanova *et al.*     [@pone.0103593-Ivanova1]
  *TSLP* (1), *BCL2* (2), *MAL* (1)                              2.14    (1.58--2.88)        0.7617                           0.10                                                                                  Set 'EED targets': genes identified by ChIP on chip as targets of the Polycomb protein *EED* in human embryonic stem cells.                                                               Benporath *et al.*   [@pone.0103593-BenPorath1]
                                                                                             0.7617                           0.10                       Set 'PRC2 targets': Polycomb Repression Complex 2(PRC) targets; identified by ChIP on chip on humanembryonic stem cells as genes that: posess thetrimethylated H3K27 mark in their promoters and are bound by *SUZ12* and *EED* Polycomb proteins.   Benporath *et al.*   [@pone.0103593-BenPorath1]
  *IRF3* (1), *TRAF5* (1), *KLK15* (1), *IL4R* (1)               0.75    (0.48--1.16)       −0.7414                           0.02                                                                                                Genes transiently induced only by the second pulse of*EGF* in 184A1 cells (mammary epithelium).                                                                               Zwang *et al.*       [@pone.0103593-Zwang1]
  *MBL2* (1), *MASP1* (1), *C6* (1)                              2.80    (1.53--5.14)       −0.8438                           0.06                                                                                                                               Lectin Induced Complement Pathway                                                                                                                 Biocarta        [@pone.0103593-Nishimura1]
                                                                                            −0.8438                           0.06                                                                                                           Genes down-regulated in liver samples of liver-specificknockout of *HNF4A*                                                                                        Ohguchi *et al.*     [@pone.0103593-Ohguchi1]
  *IRF4* (1), *TRAF5* (1), *MUC* (1)                             0.56    (0.24--1.29)       −0.8136                           0.07                                                                                        Genes up-regulated in the HMEC cells (primarymammary epithelium) upon expression of *TP53* offadenoviral vector.                                                                      Perez *et al.*       [@pone.0103593-Perez1]
  *CCR1* (1), *IL8* (1), *TNFRSF1A* (1)                          0.72    (0.43--1.20)       −0.7188                           0.09                                                                                       Genes up-regulated in circulating endothelial cells(CEC) from cancer patients compared to those fromhealthy donors                                                                   Smirrnov *et al.*     [@pone.0103593-Smirnov1]

aMutivariate Cox proportional hazard model adjusted for age, hormone status and TNM stage according to polygenic risk score estimated by using SNPs included in each pathway.

*P* value for GSEA-SNP analysis.

[Table 5](#pone-0103593-t005){ref-type="table"} showed 30 studies resulted from systematic review for survival analyses estimating effects of immune-related genetic factors on various cancers. In the studies, eighty eight SNPs in 58 immunity genes were significantly associated with the prognosis of cancer patients ([Table 6](#pone-0103593-t006){ref-type="table"}). In those results, there were 29 genes overlapped in both our study and previous studies, but no SNPs overlapped. Among them, *IL-6R*, *IL-8*, *IL-10RB*, *IL*-*12A*, and *IL*-*12B* was significantly associated with the prognosis of cancer consistent to our finding.

10.1371/journal.pone.0103593.t005

###### Characteristics of previous studies.

![](pone.0103593.t005){#pone-0103593-t005-5}

  Types of cancer               Study authors                       Genes assessed                 No. of SNPs assessed             No. of patients              No. of events   Follow-up period, yrs   Types of outcome^j^                                                                                               Adjusted covariates^k^                                                                                                               Ref
  ---------------------- ---------------------------- ------------------------------------------- ---------------------- -------------------------------------- --------------- ----------------------- --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------
  Breast                        Yang *et al*.                           *TLR4*                              4                             604                         \-                  4.9                    OS                                                                                                                  \-                                                                                                                [@pone.0103593-Yang1]
                                 You *et al*.                           *IL-21*                             4                             891                         121                 5.0                    OS                                                   age, age at menarche (years), menstrual status, BMI, pathological type, stage, ER status, PR status, family history of any cancer                                                [@pone.0103593-You1]
                                 Hu *et al*.                            *IL-2*                              2                             638                         \-                  5.0                    OS                                                                                                                  \-                                                                                                                 [@pone.0103593-Hu1]
                              DeMichele *et al*.                        *IL-6*                              4                             346                         \-                 11.2                    DFS                                                                                               age at diagnosis, race, *CYP3A4, GSTM1*                                                                                          [@pone.0103593-DeMichele1]
                               Bewick *et al.*                    *ERCC1* and *ERCC2*                       3                              95                         91         0.9 (PFS) 1.9 (BCSS)         PFS, BCSS                                                                                                              age                                                                                                              [@pone.0103593-Bewick1]
  Colorectal                     Lu *et al*.                   *REG4, BML,* and *CD209*                     15                            414                         203                 4.7                    OS                                                                                                 age at diagnosis, gender, TNM stage.                                                                                                [@pone.0103593-Lu1]
                               Castro *et al*.                      13 immune genes                         19                            582                         150                13.0                    OS                                                                                                     age at diagnosis, T, N stage.                                                                                                 [@pone.0103593-Castro1]
                              Slattery *et al*.                     11 immune genes                         50            1555[a](#nt107){ref-type="table-fn"}        309                \>5.0                   OS                                                                         age, study center, ethnic group/ethnicity, sex, TNM stage, tumor molecular phenotype                                                                     [@pone.0103593-Slattery1]
                                                                                                                                         754^b^                       171                \>5.0                   OS                                                                                                                                                                                                                             
                              Bondurant *et al*.                    13 immune genes                         59            1956[a](#nt107){ref-type="table-fn"}        309                \>5.0                   OS                                                                       age, study center, ethnic group/ethnicity, sex, AJCC stage and tumor molecular phenotype                                                                  [@pone.0103593-Bondurant1]
                                                                                                                                         954^b^                       171                \>5.0                   OS                                                                                                                                                                                                                             
  Non-small cell lung            Bi *et al*.                            *Cox-2*                             5                             136                         \-                  5.0                    OS                                                                age, sex, smoking status, KPS, weight loss, histology, clinical stages, chemotherapy, radiation dosage                                                               [@pone.0103593-Bi1]
                                 Dai *et al*.                       52 immune genes                        178                            568                         311                 6.0                    OS                                                                      smoking status, histology, stage, surgical operation, chemotherapy, or radiotherapy status                                                                    [@pone.0103593-Dai1]
                                Sung *et al*.                           *FasL*                              1                             385                         124               2.6^i^                 OS, RFS                                                                                             age, gender, smoking, tumor type, stage                                                                                             [@pone.0103593-Sung1]
                                Yuan *et al.*                          *TGF-β1*                             3                             205                         \-                1.4^i^                OS, DMFS         age, sex, race, KPS, smoking status, tumor histology, gross tumor volume, disease stage, receipt of chemotherapy or concurrent radiochemotherapy, number of cycles of chemotherapy, and radiation dose received         [@pone.0103593-Yuan1]
                                 Xue *et al.*                          *TGF-β1*                             2                             109                         85                1.2^i^                   OS                                                                 age, gender, smoking status, histology, stage, radiation technique, radiation dose, and chemotherapy                                                               [@pone.0103593-Xue1]
                              Schabath *et al.*              53 inflammation-related genes                 326                            651                         \-                2.1^i^                   OS                                                                            age, gender, race, smoking status, stage, histology and first-course treatment.                                                                       [@pone.0103593-Schabath1]
                                Guan *et al.*                   *TNF-α* and *TNFRSF1B*                      5                             225                         155                 1.9                    OS                                               age, gender, ethnicity, smoking status, tumor histology, KPS, tumor stage, node status, application of chemotherapy and radiotherapy dose                                            [@pone.0103593-Guan1]
                                Pine *et al.*                           *MBL2*                              5                    558 (white population)               405                 3.8                    OS                                                                 sex, stage (III--IV versus I-II), age at diagnosis, current smoking status, and pack-years of smoking                                                              [@pone.0103593-Pine1]
  Bladder                      Guirado *et al*.          *C13ORF31, NOD2, TLR10,* and *RIPK2*               5                             349                         66                3.9^i^                   OS                                                                                                                  \-                                                                                                              [@pone.0103593-Guirado1]
  Renal cell carcinoma         Schutz *et al*.                      70 immune genes                        290                           403^c^                       184                 5.3                    RFS                                                       ECOG performance status, clinical stage, tumour size, tumour Fuhrman grade, histology (clear cell *vs* non clear cell)                                                     [@pone.0103593-Schutz1]
                                                                                                                                         151^c^                       44                  8.8                    RFS                                                                                                                                                                                                                            
  Lymphoma                Aschebro-okkilfoy *et al*.                40 immune genes                         82                            496                         211                12.0                    OS                                                                                         age, education, stage, B-symptom, initial treatment.                                                                                 [@pone.0103593-AschebrookKilfoy1]
                             Charbonneau *et al*.                   30 immune genes                        167                           107^d^                       60                  8.3                    EFS                                                                 clinical risk score, which accounts for the effects of treatment type and FLIPI (FL) or IPI (DLBCL)                                                           [@pone.0103593-Charbonneau1]
                                                                                                                                         82^e^                        39                  8.3                    EFS                                                                                                                                                                                                                            
                              Habermann *et al*.                    44 immune genes                         73                            365                         96                  4.8                    OS                                                                                               age and clinical and demographic factors.                                                                                         [@pone.0103593-Habermann1]
                               Cerhan *et al*.                      44 immune genes                         73                            278                         59                  4.8                    OS                                                                                                  age, clinical, demographic factors                                                                                               [@pone.0103593-Cerhan1]
  Melanoma                      Lenci *et al*.                    15 type *IFN* genes                       44                            625                         174                 \-                   OS, DFS                                                                                                gender, age and Breslow thickness                                                                                               [@pone.0103593-Lenci1]
  Ovarian                       Goode *et al*.                      54 immune genes                        1536                           3665                       1529                 5.4                    OS                                                                                               study site, tumor stage, race, tumorgrade                                                                                           [@pone.0103593-Goode1]
  Pancreatic                Reid-Lombardo *et al.*              102 inflammatory genes                     1536                          400^f^                       318               2.0^i^                   OS                                                             age, sex, body mass index class, stage, margin status (R0, R1, R2), grade, tumor size, and lymph node status                                                       [@pone.0103593-ReidLombardo1]
                                                                                                                                         443^g^                       420               0.8^i^                   OS                                                                                                                                                                                                                             
                                                                                                                                         465^h^                       454               0.6^i^                   OS                                                                                                                                                                                                                             
  Osteosarcoma                 Biason *et al.*                  *XPD*, *XPG*, and *XPA*                     5                             130                         57                  3.0                    EFS                                                                                     covariate which were significant in the univariate analysis                                                                                  [@pone.0103593-Biason1]
  Esophageal                     Lee *et al.*                     *ERCC2* and *ERCC4*                       2                             400                         310                 \-                   OS, PFS                                                                                        T stage, N stage, Cell type, esophagectomy, CCRT                                                                                         [@pone.0103593-Lee2]
  Head and neck               Lundberg *et al.*                        *TGF-β1*                             1                              34                         14                  4.0                  OS, DFS                                                                              age, sex, cisplatin dose (mg/m2), RT dose (Gy) and treatment modality                                                                            [@pone.0103593-Lundberg1]
  Myeloma                     Vangsted *et al.*        *IL-1β, IL-6, IL-10, PPARγ2,* and *COX-2*            6                             348                         68                  \-                     OS                                                                                        *β*2-microglobulin, creatinine and Durie--Salmon stage                                                                                    [@pone.0103593-Vangsted1]

Colon cancer patients, ^b^Rectal cancer patients, ^c^403 cases are discovery cohort and 151 cases are validation cohort, each cohort selected from different center, ^d^Follicular lymphoma patients, ^e^Diffuse large B-cell lymphoma patients, ^f^Patients who had undergone pancreatic resection operation, ^g^Patients whose cancer locally advanced, ^h^Patients whose cancer had metastasized, ^i^Median survival time, ^j^OS, overall survival; DFS, disease free survival; RFS, relapse free survival; EFS, event free survival; DMFS, distant metastasis-free survival; BCSS, breast cancer specific survival, ^k^AJCC, american joint committee on cancer; KPS, karnofski performance status; ECOG, eastern cooperative oncology group; CCRT, concurrent neoadjuvant chemoradiotherapy; FIGO, international federation of gynecology and obstetric.

10.1371/journal.pone.0103593.t006

###### Genes that have significant SNPs of each study in the review of previous studies.

![](pone.0103593.t006){#pone-0103593-t006-6}

  Gene              SNP       Primary endpoint[a](#nt108){ref-type="table-fn"}    HR      (95% CI)       *P*     Type of cancer[b](#nt109){ref-type="table-fn"}                  Ref
  ------------- ------------ -------------------------------------------------- ------ --------------- -------- ------------------------------------------------ -----------------------------------
  *C7*            rs324058                          EFS                          1.66   (0.87--3.17)     0.04                       Lymphoma                        [@pone.0103593-Charbonneau1]
  *C9*           rs1421094                          EFS                          0.54   (0.32--0.90)     0.02                       Lymphoma                        [@pone.0103593-Charbonneau1]
  *CCR5*         rs1800940                           OS                          0.73   (0.53--1.00)      \-                        Lymphoma                      [@pone.0103593-AschebrookKilfoy1]
  *CD46*         rs2466571                          EFS                          1.49   (0.86--2.61)     0.05                       Lymphoma                        [@pone.0103593-Charbonneau1]
  *CD55*         rs2564978                          EFS                          0.52   (0.30--0.88)    \<0.01                      Lymphoma                        [@pone.0103593-Charbonneau1]
  *CD80*         rs13071247                          OS                          1.73   (1.26--2.39)    \<0.01                   Ovarian cancer                        [@pone.0103593-Goode1]
                 rs7804190                           OS                          1.14   (1.06--1.23)    \<0.01                   Ovarian cancer                        [@pone.0103593-Goode1]
  *CFH*          rs3766404                          EFS                          2.25   (1.31--3.87)    \<0.01                      Lymphoma                        [@pone.0103593-Charbonneau1]
                 rs1329423                          EFS                          0.49   (0.29--0.38)    \<0.01                      Lymphoma                        [@pone.0103593-Charbonneau1]
  *CFHR1*         rs436719                          EFS                          0.57   (0.34--0.96)     0.03                       Lymphoma                        [@pone.0103593-Charbonneau1]
  *CFHR5*        rs6694672                          EFS                          2.63   (1.41--4.92)    \<0.01                      Lymphoma                        [@pone.0103593-Charbonneau1]
  *CLU*          rs3087554                          EFS                          0.46   (0.21--1.00)     0.05                       Lymphoma                        [@pone.0103593-Charbonneau1]
  *COX-2*         rs689466                           OS                          0.58   (0.39--0.86)     0.01                        NSCLC                               [@pone.0103593-Bi1]
  *ERCC2*         rs238406                           OS                          1.64   (1.08--2.50)     0.02                  Esophageal cancer                        [@pone.0103593-Lee2]
                  rs238406                          PFS                          1.76   (1.17--2.66)     0.01                  Esophageal cancer                        [@pone.0103593-Lee2]
                 rs1799793                          BCSS                         1.90   (1.06--3.26)     0.04                    Breast cancer                         [@pone.0103593-Bewick1]
                 rs1799793                          EFS                          0.23   (0.05--0.99)     0.01                     Osteosarcoma                         [@pone.0103593-Biason1]
  *FasL*          rs763110                           OS                          1.46   (1.13--1.87)    \<0.01                       NSCLC                              [@pone.0103593-Sung1]
                  rs763110                          RFS                          1.71   (1.33--2.21)    \<0.01                       NSCLC                              [@pone.0103593-Sung1]
  *GATA3*        rs10905278                          OS                          1.82   (1.31--2.53)    \<0.01                 Pancreatic cancer                    [@pone.0103593-ReidLombardo1]
  *IFNAR1*       rs2257167                          EFS                          0.74   (0.55--1.00)     0.05                        NSCLC                            [@pone.0103593-Schabath1]
  *IFNGR1*       rs1327474                           OS                          0.69   (0.50--0.94)     0.02                  Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs9376267                           OS                          1.37   (1.09--1.73)     0.01                  Colorectal cancer                      [@pone.0103593-Slattery1]
  *IFNGR2*       rs2834211                           OS                          1.32   (1.01--1.72)     0.04                  Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs2834213                           OS                          2.04   (1.16--3.57)     0.01                  Colorectal cancer                      [@pone.0103593-Slattery1]
  *IFNW1*        rs10964859                          OS                          1.80   (1.02--3.16)     0.04                       Melanoma                           [@pone.0103593-Lenci1]
  *IL-10RB*      rs8128184                          EFS                          1.59   (1.11--2.29)     0.01                        NSCLC                            [@pone.0103593-Schabath1]
  *IL-12A*       rs2243148                          EFS                          1.28   (1.03--1.58)     0.03                        NSCLC                            [@pone.0103593-Schabath1]
  *IL-12B*       rs3212227                           OS                          1.83   (1.09--3.06)    \<0.01                      Lymphoma                           [@pone.0103593-Cerhan1]
  *IL-13*        rs1295683                          EFS                          1.39   (1.03--1.87)     0.03                        NSCLC                            [@pone.0103593-Schabath1]
  *IL-1A*        rs3783546                           OS                          2.07   (1.28--3.36)     0.02                  Colorectal cancer                     [@pone.0103593-Bondurant1]
                 rs1800587                           OS                          1.90   (1.26--2.87)    \<0.01                      Lymphoma                         [@pone.0103593-Habermann1]
  *IL-1B*        rs1143623                           OS                          1.37   (1.09--1.72)     0.01                  Colorectal cancer                     [@pone.0103593-Bondurant1]
                 rs1143627                           OS                          0.50   (0.30--1.00)     0.04                       Myeloma                           [@pone.0103593-Vangsted1]
  *IL-1RN*        rs454078                           OS                          1.93   (1.11--3.34)     0.03                       Lymphoma                           [@pone.0103593-Cerhan1]
  *IL-2*         rs2069763                           OS                          1.43   (1.15--3.82)      \-                     Breast cancer                           [@pone.0103593-Hu1]
                 rs2069762                           OS                          1.80   (1.06--3.05)     0.01                       Lymphoma                           [@pone.0103593-Cerhan1]
  *IL-21*        rs12508721                          OS                          0.45   (0.30--0.67)    \<0.01                   Breast cancer                          [@pone.0103593-You1]
  *IL-23R*       rs6682925                           OS                          1.34   (1.05--1.70)      \-                         NSCLC                              [@pone.0103593-Dai1]
  *IL-3*          rs181781                           OS                          2.47   (1.11--5.53)     0.03                  Colorectal cancer                     [@pone.0103593-Bondurant1]
  *IL-5*         rs2069807                           OS                          4.56   (1.98--10.5)    \<0.01                      Lymphoma                         [@pone.0103593-Habermann1]
                 rs2069818                           OS                          5.58   (1.66--18.6)     0.01                       Lymphoma                           [@pone.0103593-Cerhan1]
  *IL-5R*        rs11713419                          OS                          6.60   (2.42--18.02)     \-                         NSCLC                              [@pone.0103593-Dai1]
  *IL-6*         rs1800796                           OS                          0.42   (0.23--0.77)      \-                        Lymphoma                      [@pone.0103593-AschebrookKilfoy1]
                 rs1800797                          DFS                          1.60   (1.09--2.35)     0.02                    Breast cancer                       [@pone.0103593-DeMichele1]
  *IL-6R*        rs4240872                          EFS                          0.75   (0.59--0.95)     0.02                        NSCLC                            [@pone.0103593-Schabath1]
  *IL-8*           rs4073                            OS                          2.14   (1.26--3.63)      \-                        Lymphoma                           [@pone.0103593-Cerhan1]
                 rs2227307                           OS                          1.90   (1.12--3.22)      \-                        Lymphoma                           [@pone.0103593-Cerhan1]
                 rs2227306                           OS                          1.96   (1.07--3.28)      \-                        Lymphoma                           [@pone.0103593-Cerhan1]
                 rs12506479                         EFS                          1.32   (1.08--1.62)     0.01                        NSCLC                            [@pone.0103593-Schabath1]
  *IL-8RB*       rs1126579                           OS                          1.61   (1.05--2.46)     0.02                  Colorectal cancer                     [@pone.0103593-Bondurant1]
                 rs1126580                           OS                          2.11   (1.28--3.50)    \<0.01                      Lymphoma                         [@pone.0103593-Habermann1]
  *IRF2*         rs12504466                          OS                          1.51   (1.14--1.99)    \<0.01                 Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs13116389                          OS                          1.38   (1.09--1.75)     0.01                  Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs2797507                           OS                          0.77   (0.61--0.98)     0.03                  Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs3775582                           OS                          0.67   (0.50--0.89)     0.01                  Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs7655800                           OS                          1.33   (1.04--1.70)     0.02                  Colorectal cancer                      [@pone.0103593-Slattery1]
                  rs793801                           OS                          1.39   (1.01--1.91)     0.04                  Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs1425551                           OS                          1.50   (1.03--2.18)     0.04                  Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs3756094                           OS                          0.36   (0.20--0.66)    \<0.01                 Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs3822118                           OS                          1.47   (1.08--2.01)     0.02                  Colorectal cancer                      [@pone.0103593-Slattery1]
                  rs807684                           OS                          0.30   (0.14--0.66)    \<0.01                 Colorectal cancer                      [@pone.0103593-Slattery1]
                 rs1044873                           OS                          1.32   (1.04--1.68)     0.03                  Colorectal cancer                      [@pone.0103593-Slattery1]
                  rs305083                           OS                          1.31   (1.04--1.65)     0.02                  Colorectal cancer                      [@pone.0103593-Slattery1]
  *IRF6*         rs2013196                           OS                          1.29   (1.02--1.63)     0.03                  Colorectal cancer                      [@pone.0103593-Slattery1]
  *LRRC32*       rs3781699                           OS                          2.32   (1.45--3.71)    \<0.01                   Ovarian cancer                        [@pone.0103593-Goode1]
                 rs7944357                           OS                          2.04   (1.34--3.10)    \<0.01                   Ovarian cancer                        [@pone.0103593-Goode1]
  *MBL2*         rs7096206                           OS                          0.55   (0.42--0.73)    \<0.01                       NSCLC                              [@pone.0103593-Pine1]
  *MET*          rs11762213                         RFS                          1.86   (1.17--2.95)     0.01                  Renal cell cancer                       [@pone.0103593-Schutz1]
  *NFKB*         rs7157810                           OS                          1.43   (1.16--1.75)    \<0.01                 Pancreatic cancer                    [@pone.0103593-ReidLombardo1]
  *NOD2*         rs9302752                           OS                          3.19   (2.04--4.34)      \-                     Bladder cancer                       [@pone.0103593-Guirado1]
  *NOS3*         rs1799983                           OS                          1.39   (1.14--1.70)    \<0.01                 Pancreatic cancer                    [@pone.0103593-ReidLombardo1]
  *REG4*         rs2994809                          DFS                          2.00   (1.18--3.39)     0.01                  Colorectal cancer                         [@pone.0103593-Lu1]
                 rs2994811                           OS                          1.35   (1.02--1.78)     0.03                  Colorectal cancer                         [@pone.0103593-Lu1]
  *RGS1*         rs10921202                          OS                          2.93   (1.77--4.84)    \<0.01                   Ovarian cancer                        [@pone.0103593-Goode1]
  *RIPK1*        rs2326173                           OS                          1.44   (1.20--1.74)    \<0.01                 Pancreatic cancer                    [@pone.0103593-ReidLombardo1]
  *SOCS3*        rs8064821                           OS                          0.65   (0.49--0.87)    \<0.01                 Pancreatic cancer                    [@pone.0103593-ReidLombardo1]
  *STAT1*        rs12693591                          OS                          0.68   (0.55--0.86)    \<0.01                 Pancreatic cancer                    [@pone.0103593-ReidLombardo1]
  *TGF-β1*        rs10469                            OS                          1.46   (1.01--2.11)     0.04                        NSCLC                              [@pone.0103593-Yuan1]
                 rs1982073                          DMFS                         1.59   (1.01--2.50)     0.05                        NSCLC                              [@pone.0103593-Yuan1]
                 rs1982073                          DFS                          3.23   (1.19--8.77)     0.02                        HNSCC                            [@pone.0103593-Lundberg1]
                 rs1800469                           OS                          0.46   (0.25--0.87)     0.02                        NSCLC                              [@pone.0103593-Xue1]
  *TGFBR1*       rs10512263                         EFS                          0.59   (0.37--0.94)     0.03                        NSCLC                            [@pone.0103593-Schabath1]
                   rs868                            EFS                          1.28   (1.01--1.61)     0.04                        NSCLC                            [@pone.0103593-Schabath1]
  *TGFBR2*       rs2043136                          EFS                          0.74   (0.58--0.95)     0.02                        NSCLC                            [@pone.0103593-Schabath1]
  *TLR1*         rs5743551                           OS                          0.78   (0.62--0.97)      \-                         NSCLC                              [@pone.0103593-Dai1]
  *TLR10*        rs4129009                           OS                          0.49   (0.18--0.80)      \-                     Bladder cancer                       [@pone.0103593-Guirado1]
  *TLR3*         rs3775291                           OS                          1.93   (1.14--3.28)      \-                   Colorectal cancer                       [@pone.0103593-Castro1]
                 rs3775291                           OS                          1.37   (1.09--1.73)      \-                         NSCLC                              [@pone.0103593-Dai1]
  *TLR4*         rs11536889                          OS                          1.38   (1.09--3.12)     0.02                    Breast cancer                          [@pone.0103593-Yang1]
  *TNFRSF10B*    rs11785599                         EFS                          1.41   (1.16--1.70)    \<0.01                       NSCLC                            [@pone.0103593-Schabath1]
  *TNFRSF1B*     rs1061622                           OS                          0.38   (0.15--0.94)     0.04                        NSCLC                              [@pone.0103593-Guan1]
  *TNFRSF4*      rs3753348                           OS                          3.41   (1.65--7.05)    \<0.01                   Ovarian cancer                        [@pone.0103593-Goode1]

EFS, event free survival; OS, overall survival; RFS, relapse free survival; DFS, disease free survival; DMFS, distant metastasis-free survival; BCSS, breast cancer specific survival.

DLBCL, diffuse large B-cell lymphoma; NSCLC, non-small cell lung cancer; FL, follicular lymphoma; HNSCC, head and neck squamous cell carcinoma.

Discussion {#s4}
==========

In this study, we found that the rs1952438 in the suppressors of cytokine signaling (*SOCS4)* gene, rs2289278 in the thymic stromal lymphopoietin (*TSLP*) gene and rs2074724 in the hepatocyte growth factor (*HGF*) gene were highly associated with a poor prognosis of breast cancer. Moreover, the polygenic risk score model with genetic variations of immunity-related genes showed that the hazard of DFS of patients was significantly increased as high-risk alleles accumulated. In the GSEA-SNP analysis, 18 pathways significantly affected breast cancer prognosis.

The rs1952438 is located in the intron region of *SOCS4* gene. SOCS family are rapidly induced by activated STATs and negatively regulate JAK/STAT pathway by a classical feedback loop [@pone.0103593-Hilton1]. Furthermore, other signal molecules such as FAK, IRS, p65, GR which are related with carcinogenesis, are regulated by SOCS proteins [@pone.0103593-Emanuelli1]--[@pone.0103593-Ueki1]. In addition, there are several previous study which reported that people who have higher expression level of *SOCS4* are likely remained disease free status compared to those who developed recurrence [@pone.0103593-Sasi1]. In the view of previous studies which explain functional importance of *SOCS4* and results of present study, it might be assumed that rs1952438 is associated with poorer prognosis of breast cancer by declining expression level of *SOCS4*.

The rs2289278 is found in intron 2 of the long-form of *TSLP* and in the 5′ untranslated region of the short-form of *TSLP* [@pone.0103593-Liu2]. *TSLP* is a member of the IL-2 cytokine family and a distant paralog of IL-7. *TSLP* may have an important role in tumor progression by activating CD4*+* T cells, inducing the expressing of OX40L in dendritic cells (DCs), and producing Th2-type cytokines and B-cell growth factor [@pone.0103593-Ziegler1]. A recent study has shown that breast cancer cells have high expression levels of *TSLP*, indicating that the *TSLP* may be critical in the development of breast cancer [@pone.0103593-Olkhanud1]. It is that high expression level of TSLP in cancer increases the Th2 level [@pone.0103593-Ziegler1]. Furthermore, Th2 cytokines promote disease progres­sion through the increased survival of cancer cells, M2 macrophage differentia­tion, and fibrosis [@pone.0103593-Olkhanud1], [@pone.0103593-PedrozaGonzalez1]. Thus, TSLP may be an important factor of breast tumor progression and the prognosis of a patient.

The rs2074724 is located in the intron of *HGF*. *HGF* is known to activate angiogenesis of tumors as well as cell-cell interactions, matrix adhesion, migration, invasion [@pone.0103593-Parr1]. Moreover, breast cancer patients with a high HGF concentration had a significantly poor prognosis when compared to those with a low HGF concentration [@pone.0103593-Yamashita1]. Therefore, HGF level was found to be the most important independent factor in predicting the prognosis of breast cancer.

In the GSEA-SNP analysis, there are 18 significant pathways; among these pathways, gene set from Kyng et al [@pone.0103593-Kyng1] which included rs1952438 in *SOCS4* gene and rs2074724, and rs5745752 in *HGF* gene is described that environmental stress such as 4-nitroquinoline-1-oxide (4NQO) elicited DNA damage specific gene expression changes of up to 10. In short, it can be expected that those SNPs included in the pathway can up-regulate breast cancer progression and result in poor prognosis by influencing on environmental response, although there are not precise result in this assumption.

'Myc tagets1' gene set from Benporath et al [@pone.0103593-BenPorath1] which included rs12458289 and rs9989529 in *BCL2* gene, and rs2142097 in *NBN* gene is shown as the most significant gene set. Benporath et al describe that targets of *Nanog*, *Oct4*, *Sox2* and *c-Myc* are more frequently associated in poorly differentiated tumors than in well-differentiated tumors. *c-Myc* is well known to directly regulate the expression of *NBN* gene involved in DNA double-strand break repair and can result in chromosomal instability, cellular proliferation defects leading to increased more aggressive and metastatic tumor latency [@pone.0103593-Chiang1], [@pone.0103593-Shimada1]. *BCL2* and *c-Myc* are known to make the negative feedback loop in breast cancer cell line [@pone.0103593-Gaire1]. Taking all these consideration of both Benporath et al and results of present study to account, it is can be deduced that rs12458289, rs9989529, and rs2142097 might be associated with the prognosis of breast cancer by interacting with *c-MYC* gene.

To support the indirectly functional effects of our results, we attempted to find potential functional SNPs in *SOCS4*, *HGF*, *TSLP* and genes included in GSEA-SNP using UCSC database [@pone.0103593-Kent1] and checked the LD between the potential functional SNPs and our findings. [Table S2](#pone.0103593.s002){ref-type="supplementary-material"} show the functional SNPs studied in this study and functional SNPs in LD with those SNPs, generally to affect histone modification, DNA methylation, and binding affinity of several transcription factors located in 5′UTR or 3′UTR. For example, transcription activity of *IL-8* is influenced by rs4073 which located in promoter region of *IL-8* [@pone.0103593-Hull1] and the variant increased the risk of mortality in follicular lymphocytic leukemia by increasing production of *IL-8* [@pone.0103593-Cerhan1]. As a result, it is possibly anticipated that those potential SNPs may influence to breast cancer prognosis by regulating the epigenetic and transcriptional pathway.

Several previous reports have evaluated the associations of immunity gene polymorphism and breast cancer prognosis [@pone.0103593-Yang1]--[@pone.0103593-DeMichele1]. They suggested that the variants of *ERCC2, TLR4*, *IL-2*, *IL-6*, and *IL-21* genes had associations with breast cancer prognosis respectively. However, those genes were not replicated in present study. In the other types of cancer studies, *IL-6R*, *IL-8*, *IL-10RB*, *IL-12A*, and *IL-12B* genes were consistently associated with cancer prognosis between our study and theirs. However, there were few consistent SNPs with cancer prognosis in our review of the literature, which may result from various cancer targets, different ethnicities, and different prognostic factors in the models and statistical power.

In this study, there are several limitations including a small sample size and absence of an external validation study. Since the power of this study was low to detect accurate results, the results of this study are carefully interpreted, although the significance levels of top 3 SNPs passed the FDR test with significance (*p\<*0.05) and the internal validity was confirmed by the cross-validation. In addition, polygenic risk score model and GSEA-SNP are conducted with whole significant SNPs which include insignificant SNPs at FDR p-value greater than 0.05. Tag SNPs selected based on the data of a Caucasian population and lack of breast cancer subtype information were also limitations of this study. In the systematic review-level, the summary measure and synthesis of the results were not calculated because various genes and the variations related to immune response were the focus. However, the strength of this study is that lots of genetic factors in immune-related genes were covered at once. Moreover, it attempted to apply the candidate gene approach to cover the pathway of immunity-related genetic factors with breast cancer prognosis in Asian women.

In conclusion, our study found that common variants in the *SOCS4*, *TSLP* and *HGF* genes might be related with breast cancer prognosis in Korean women. Hazard of DFS in patients was significantly increased when high-risk alleles were accumulated. Therefore, our results suggest that genetic polymorphisms in immunity-related genes have relevance to breast cancer prognosis among Korean women. Further large-scale functional studies are needed to confirm our findings.
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